In vitro studies of water-stable cationic carbosilane dendrimers as delivery vehicles for gene therapy against HIV and hepatocarcinoma

Current Medicinal Chemistry

Volumn 19, Issue 29, 2012, Pages 5052-5061

  De Las Cuevas, N ^a,b   Garcia Gallego S ^b,c   Rasines, B ^b,c   De La Mata, F J ^b,c   G Guijarro, L ^c,d   Munoz Fernandez M A ^a,c   Gomez R ^c  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c UNIVERSITY OF ALCALÁ   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cancer; Carbosilane; Dendrimer; Drug delivery; Gene therapy; HIV; Oligonucleotides; SiRNA; Transfection agent

Indexed keywords

AMMONIA; AZATHIOPRINE; CARBOSILANE; DENDRIMER; INSULIN RECEPTOR SUBSTRATE; INSULIN RECEPTOR SUBSTRATE 4; NANOCONJUGATE; NUCLEIC ACID; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LIVER CELL CARCINOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SENSITIZATION; SYNTHESIS;

CARCINOMA, HEPATOCELLULAR; CATIONS; DENDRIMERS; GENETIC THERAPY; HIV INFECTIONS; HUMANS; LIVER NEOPLASMS; SILANES; TRANSFECTION;

EID: 84870418047     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311209025052     Document Type: Article

References (43)

1. (a) Verma, I.M.; Somia, N. Gene therapy-promises, problems and prospects. Nature, 1997, 389, 239-242.
2. (b) Crooke, S.T. Advances in understanding the pharmacological properties of antisense oligonucleotides. Adv. Pharmacol., 1997, 40, 1-49.
3. (c) Roush, W. Antisense aims for a renaissance. Science, 1997, 276, 1192-1193.
4. (d) Uhlmann, E.; Peyman, A. Antisense oliglonucleotides: a new therapeutic principles. Chem. Rev. 1990, 90, 543-584.
5. Carter, B.J. In: Viral vectors for gene therapy. Biotechnology; Mountain, A.; Ney, U.; Schomburg, D., Eds.; Wiley-VCH, 1998; Vol. 5a, pp. 397-421.
6. (a) Hacein-Bey-Abina, S.; von Kalle, C.; Shmidt, M.; Le Deist, F.; Wulffraat, N.; McIntyre, E.; Radford, I.; Villeval, J.L.; Fraser, C.C.; Cavazzana-Calvo, M. A serious adverse event after successful gene therapy for X-linked severe combine immunodeficiency. N. Engl. J. Med, 2003, 348(3), 255.
7. (b) Verma, M.I. A tumultuous year for gene therapy. Mol. Ther. 2000, 2, 415-416.
8. (a) Zabner, J. Cationic lipids used in gene transfer. Adv. Drug. Deliv. Rev., 1997, 27, 17-28.
9. (b) Berh, J.P. Synthetic gene transfer vectors. Acc. Chem. Res. 1993, 26, 274-278.
10. (a) Fréchet, J.M.J.; Tomalia, D.A. In: Dendrimers and Other Dendritic Polymers. Wiley, 2002.
11. (b) Liu, M.; Fréchet, J.M.J. Designing dendrimers for drug delivery. Pharmaceutical Science & Technology Today, 1999, 2, 393-401.
12. (c) Estefand, R.; Tomalia, D.A. Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discovery Today, 2001, 6, 427-436.
13. Tomalia, D.A.; Baker, H.; Dewald, J.; Hall, M.; Kallos, G.; Martin, S.; Roeck, J.; Ryder, J.; Smith, P. A new class of polymers: starburst-dendritic polymers. Polym. J, 1985, 17, 117-132.
14. Malik, N., Wiwattanapatapee, R.; Klopsch, R.; Lorenz, K.; Frey, H.; Weener, J.W.; Meijer, E.W.; Paulus, W.; Duncan, R. Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labeled polyamidoamine dendrimers in vivo. J. Control. Release, 2000, 65, 133-148.
15. (a) Hawker, C.J.; Fréchet, J.M.J. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J. Am. Chem. Soc., 1990, 112, 7638.
16. (b) Liu, M.; Kono, K.; Fréchet, J. M. J. Water-soluble dendritic unimolecular micelles: Their potential as drug delivery agents. J. Control. Release, 2000, 65, 121-131.
17. (c) Liu, M.; Kono, K.; Fréchet, J.M. Water-soluble dendrimer-poly(ethylene glycol) starlike conjugates as potential drug carriers. J. Polym. Sci., 1999, A37, 3492-3503.
18. (a) Loup, C.; Zanta, M.A.; Caminade, A.M.; Majoral, J.P.; Meunier, B. Preparation of water-Ssluble cationic phosphorus-containing dendrimers as DNA transfecting agents. Chem. Eur. J. 1999, 5, 3644-3650.
19. (b) Caminade, A.M.; Majoral, J.P. Water-soluble phosphorus-containing dendrimers. Progr. Polym. Sci. 2005, 30, 491-505.
20. (a) Haag, R.; Sunder, A.; Stumbé J.-F. An approach to glycerol dendrimers and pseudo-dendritic polyglycerols. J. Am. Chem. Soc., 2000, 122, 2954-2955.
21. (b) Frey, H.; Haag, R. Dendritic polyglycerol: A new versatile biocompatible material. Rev. Mol. Biotech, 2002, 90, 257-267.
22. (c) Boysen, M.M.K.; Elsner, K.; Sperling, O.; Lindhorts, T. K. Glycerol and glycerol glycol glycodendrimers. Eur. J. Org. Chem., 2003, 4376-4386.
23. Fuchs, S.; Kapp, T.; Otto, H.; Schöneberg T.; Franke, P.; Gust, R.; Schüter, D. A surface-modified dendrimer set for potential applications as drug delivery vehicles: synthesis, in vitro toxicity, and intracellular localization. Chem. Eur. J., 2004, 10, 1167-1192.
24. Neerman, M.F.; Zhang, W.; Parrish, A.R.; Simanek, E. E. In-vitro and invivo evaluation of melamine Dendrimer as a vehicle for drug delivery. Int. J. Pharm., 2004, 281, 129-132.
25. Merino, S.; Brauge, L.; Caminade, A.M.; Majoral, J.P.; Taton, D.; Gnanou, Y. Synthesis and characterization of linear, hyperbranched, and gendrimerlike polymers constituted of the same repeating unit. Chem. Eur. J., 2001, 7, 3095-3105.
26. (a) Bermejo, J.F.; Ortega, P.; Chonco, L.; Eritja, R.; Samaniego, R.; Müllner, M.; de Jesús, E.; de la Mata, F.J.; Flores, J.C.; Gómez, R.; Muñoz-Fernández, M.A. Water-soluble carbosilane dendrimers: synthesis, biocompatibility and complexation with oligonucleotides; evaluation for medical applications. Chem. Eur. J. 2007, 13, 483-495.
27. (b) Ortega, P.; Bermejo, J.F.; Chonco, L.; de Jesús, E.; de la Mata, F.J.; Fernández, G.; Flores, J.C.; Gómez, R.; Serramía, M.J.; Muñoz-Fernández, M.A. Novel water-soluble carbosilane dendrimers: synthesis and biocompatibility. Eur. J. Inorg. Chem. 2006, 7, 1388-1396.
28. (a) van der Made, A.W.; van Leeuwen, P.W.N.M. Silane dendrimers. J. Chem. Soc., Chem. Commun. 1992, 1400-1401.
29. (b) van der Made, A.W.; van Leeuwen, P.W.N.M.; De Wilde, J.C.; Brandes, R.A.C. Dendrimeric silanes. Adv. Mater. 1993, 5, 466-468.
30. (c) Zhou, L.L.; Roovers, J. Synthesis of novel carbosilane dendritic macromolecules. Macromolecules 1993, 26, 963-968.
31. (d) Seyferth, D.; Son, D.Y.; Rheingold, A.L.; Ostrander, R.L. Synthesis of an organosilicon dendrimer containing 324 Si-H bonds. Organometallics 1994, 13, 2682-2690.
32. (e) Cuadrado, I.; Morán, M.; Losada, J.; Casado, C.M.; Pascual, C.; Alonso, B.; Lobete, F. Advances in dendritic Macromolecules; G. R. Newkome, Ed.; JAI press Inc: Greenwich CT, 1996, 3, 151-195.
33. (a) Chonco, L.; Bermejo, J.F.; Ortega, P.; Shcharbin, D.; Pedziwiatr, E.; Klajnert, B.; De la Mata, F.J.; Eritja, R.; Gómez, R.; Bryszewska, M.; Muñoz-Fernández, M.A. Water-soluble carbosilane dendrimers protect phosphorothioate oligonucleotides from binding to serum proteins. Org.& Biomol. Chem. 2007, 5, 1886-1893.
34. (b) Weber, N.; Ortega, P.; Clemente, M.I; Shcharbin, D.; Bryszewska, M.; De la Mata, F.J.; Gómez, R.; Muñoz-Fernández, M.A. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV infected lymphocytes. J. Control. Release 2008, 132, 55-64.
35. Posadas, I.; López-Hernández, B.; Clemente, M.I.; Jiménez, J.L.; Ortega, P.; De la Mata, F.J.; Gómez, R.; Muñoz-Fernández, M.A.; Cena, V. Highly efficient transfection of rat cortical neurons using carbosilane dendrimers unveils a neuroprotective role for HIF-1α in early chemical hypoxia-mediated neurotoxicity. Pharm. Res. 2009, 26, 1181-1191.
36. Rasines, B.; Hernández-Ros, J.M.; de las Cuevas, N.; Copa-Patiño, J.L.; Soliveri, J.; Muñoz-Fernández, M.A.; Gómez, R.; De la Mata, F.J. Waterstable ammonium-terminated carbosilane dendrimers as efficient antibacterial agents. Dalton Trans., 2009, 40, 8704-8713.
37. Perrin, D.D.; Armego, W.L.F.; Perrin, D.R. Purification of Laboratory Chemicals, 3rd ed.; Pergamon Press Ltd.: Oxford, 1988.
38. García-Merino, I.; de las Cuevas, N.; Jiménez, J.J.; Gallego, J.; Gómez C.; Prieto, C.; Serramía, M. A.; Lorente, R.; Muñoz-Fernández M.A.; Spanish HIV BioBank. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology, 2009, 6
39. Rubinstein, R.; Colby, R. H. Polymer Physics, Oxford University Press, 2003
40. Escribano, O.; Fernández-Moreno, M.D.; Zueco, J.A.; Menor, C.; Fueyo, J.; Ropero, R.M.; Díaz-Laviada, I.; Román, I.D.; Guijarro, L.G. Insulin receptor substrate-4 signalling in quiescent rat hepatocytes and in regenerating rat liver. Hepatology, 2003, 37, 1461-1469.
41. Cuevas, E.P.; Escribano, O.; Chiloeches, A.; Ramírez Rubio, S.; Román, I.D.; Fernández-Moreno, M.D.; Guijarro, L.G. Role of insulin receptor substrate-4 in IGF-I-stimulated HEPG2 proliferation. J. Hepatol., 2007, 46, 1089-1098.
42. Cuevas, E.P.; Escribano, O.; Monserrat, J.; Martínez-Botas, J.; Sánchez, M.G.; Chiloeches, A.; Hernández-Breijo, B.; Sánchez-Alonso, V.; Román, I.D.; Fernández-Moreno, M.D.; Guijarro, L.G. RNAi-Mediated Silencing of Insulin Receptor Substrate-4 Enhances Actinomycin D-and Tumor Necrosis Factor-alpha-Induced Cell Death in Hepatocarcinoma Cancer Cell Lines. J. Cell Biochem., 2009, 108, 1292-1301.
43. Hernández-Breijo, B.; Monserrat, J.; Ramírez-Rubio, S.; Cuevas, E.P.; Vara, D.; Díaz-Laviada, I.; Fernández-Moreno, M.D.; Román, I.D.; Gisbert, J.P.; Guijarro, L.G. Preclinical evaluation of azathioprine plus buthionine sulfoximine in the treatment of human hepatocarcinoma and colon carcinoma. World Journal of Gastroenterology, 2011, 17(34), 3899-3911.